Reliability of a medication adherence measure in an outpatient setting

American Journal of the Medical Sciences

Volumn 330, Issue 3, 2005, Pages 128-133

  Krousel Wood, Marie ^a,c   Muntner, Paul ^a,b   Jannu, Ann ^a   Desalvo, Karen ^a,b   Re, Richard N ^a  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Adherence; Hill bone compliance; Hypertension; Reliability

Indexed keywords

ANTIHYPERTENSIVE AGENT; SODIUM CHLORIDE;

ACADEMIC ACHIEVEMENT; ADULT; AGE; AGED; ARTICLE; COMMUNITY; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DEMOGRAPHY; EUROPEAN AMERICAN; FEMALE; HILL BONE COMPLIANCE TO HIGH BLOOD PRESSURE THERAPY SCALE; HUMAN; HYPERTENSION; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; QUESTIONNAIRE; RATING SCALE; RELIABILITY; SALT INTAKE; STATISTICAL ANALYSIS; UNITED STATES;

EID: 25444523270     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200509000-00006     Document Type: Article

References (28)

1. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC VII Report. JAMA 2003;289:2560-72.
2. Krousel-Wood MA, Muntner P, He J, et al. Primary prevention of essential hypertension. Med Clin North Am 2004; 88:223-38.
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension. Lancet 2005;365;217-23.
4. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404.
5. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States (1988-2000). JAMA 2003;290:199-206.
6. Burnier M, Santschi V, Favrat B, et al. Monitoring compliance in resistant hypertension: an important step in patient management. J Hypertens 2003;21(Suppl 2):537-42.
7. Turpin K, Jungkind K, Salvucci L. The HEDIS® performance NAVIGATOR for controlling high blood pressure: a resource to assist health plans and improve patient adherence. Dis Manag 2003;6:43-51.
8. Sackett DL. Introduction. In: Sackett DL, Haynes RB, editors. Compliance with therapeutic regimens. Baltimore: Johns Hopkins University Press; 1976. p. 1-6.
9. Elliott WJ. Compliance-and improving it-in hypertension. Manag Care P&T Digest 2003;12:56-61.
10. Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-62.
11. Morisky DE, Green W, Levine DM, et al. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74.
12. Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy scale. Prog Cardiovasc Nurs 2000;15:90-6.
13. Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219-28.
14. Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164-70.
15. Roter D, Hall J, Merisca R, et al. Effectiveness of interventions to improve patient compliance: a meta-analysis. Med Care 1998;36:1138-61.
16. Steele DT, Jackson TC, Gutmann MC. Have you been taking your pills? The adherence monitoring sequence in the medical interview. J Fam Pract 1990;30:294.
17. Prisant LM, Moser M. Hypertension in the elderly: can we improve results of therapy? Arch Intern Med 2000;160:283-9.
18. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997;277:739-45.
19. Wright JT Jr., Bakris G, Greene T, et al. African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31.
20. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;21:1214-8.
21. Shea S, Misra D, Ehrlich M, et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992;82:1607-12.
22. Monane M, Bohn RL, Gurwitz JH, et al. A population-based study of compliance with antihypertensive therapy: role of age, gender and race. Am J Pub Health 1996;86:1805-9.
23. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992;8:141-6.
24. Furberg CD, Black DM. The Systolic Hypertension in The Elderly Pilot Program: methodological issues. Eur Heart Journal 1988;9:223-7.
25. Caro JJ, Salas M, Speckman JL et al. Persistence with treatment for hypertension in actual practice. CMAJ 1999; 160:31-7.
26. Caro JJ, Speckman JL, Salas M et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999;160: 41-6.
27. Marentette MA, Gerth WC, Billings DK, et al. Antihypertensive persistence and drug class. Can J Cardiol 2002;18: 649-56.
28. Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004;164:722-32.